Viridian Therapeutics, Inc.VRDNNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+39.4%
5Y CAGR+48.4%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+39.4%/yr
vs +33.6%/yr prior
5Y CAGR
+48.4%/yr
Recent deceleration
Acceleration
+5.8pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
7.2x
Strong expansion
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$95.31M+56.0%
2024$61.08M-35.7%
2023$95.00M+170.0%
2022$35.18M+36.3%
2021$25.80M+94.5%
2020$13.27M+13.9%
2019$11.65M+5.4%
2018$11.05M+1.3%
2017$10.91M+14.0%
2016$9.57M-